Celyad Oncology SA
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Celyad Oncology SA generated cash of -$15,202,000, which is more than the previous year. Cash used in financing activities reached the amount of $9,355,000 last year. Net change in cash is therefore -$5,441,000.
Cash Flow
| 2014 | -17.41M | -1.76M | 27.75M |
|---|---|---|---|
| 2015 | -27.30M | -10.69M | 110.53M |
| 2016 | -24.69M | -30.15M | 3.03M |
| 2017 | -44.44M | 17.61M | 605K |
| 2018 | -27.24M | 607K | 43.92M |
| 2019 | -28.20M | 8.98M | 18.27M |
| 2020 | -27.66M | 157K | 5.39M |
| 2021 | -26.64M | -126K | 39.52M |
| 2022 | -28.01M | 7.20M | 3.24M |
| 2023 | -15.20M | 407K | 9.35M |
0QFK.L Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 12.44M | 30.01M | 17.23M | 39.33M | 40.54M | 23.25M | 48.35M | 100.17M | 27.63M | 19.05M |
Operating activities | ||||||||||
Net income | -8.44M | -40.93M | -26.51M | -17.20M | -28.63M | -37.42M | -56.39M | -23.60M | -29.11M | -16.45M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 794K | 1.44M | 1.52M | 1.83M | 1.78M | 1.11M | 1.71M | 1.51M | 1.03M | 870K |
Stock-based compensation expense | 935K | 1.62M | 2.17M | 2.78M | 2.77M | 0 | 2.56M | 2.84M | 796K | 1.52M |
| Deferred income tax benefit | 935K | 1.62M | 2.17M | 2.78M | 2.77M | 0 | 2.56M | 2.84M | 796K | 1.52M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -1.20M | 306K | 0 | 0 | -1.77M | -1.45M | -832K | -1.01M | 653K | -2.04M |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 0 | 0 | 0 | 0 | 1.16M | 1.94M | -2.48M | -740K | 1.06M | 0 |
Cash generated by operating activities | -15.20M | -28.01M | -26.64M | -27.66M | -28.20M | -27.24M | -44.44M | -24.69M | -27.30M | -17.41M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | -307K | 0 | -26.56M | -10.74M | -34.23M | -5M | 0 |
Investments In Property Plant And Equipment | -934K | -123K | -393K | -319K | -622K | -1.76M | -858K | -1.78M | -838K | -590K |
Acquisitions Net | 0 | 6M | 0 | 235K | 0 | 74K | -5.10M | -1.48M | -5.18M | -1.5M |
Cash generated by investing activities | 407K | 7.20M | -126K | 157K | 8.98M | 607K | 17.61M | -30.15M | -10.69M | -1.76M |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 36.56M | 0 | 16.44M | 43.01M | 625K | 0 | 109.15M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | -124K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -145K | -896K | -37K | -192K | -1.48M | -201K | -32.99K | -766K | 263K | -306K |
Cash used in financing activities | 9.35M | 3.24M | 39.52M | 5.39M | 18.27M | 43.92M | 605K | 3.03M | 110.53M | 27.75M |
Net Change In Cash | -5.44M | -17.57M | 12.78M | -22.10M | -1.20M | 17.28M | -25.10M | -51.81M | 72.54M | 8.57M |
Cash at end of period | 7.00M | 12.44M | 30.01M | 17.23M | 39.33M | 40.54M | 23.25M | 48.35M | 100.17M | 27.63M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |